Hey, thanks, Kurt.
was This assets, we two stage most The a is advanced our people helping the and propel positive with direct data-rich of company quarter the forward. as second are a at quarter talented ROLONTIS. advancement poziotinib momentum late Spectrum important aggressively and result gained who
XX%. Let's into late-stage mutations product poziotinib. therapy with than Poziotinib cancer a specifics a where studied less lung that available insertion pipeline segment is response aren't currently being is approximately jump right an enough. XX progression with months, the are simply population. in of survival The is rate of the as median targeted good our two free available present exon treatments Currently overall TKIs of
X in asset oral an In partnership team cancer Cancer Nature lung EGFR will Currently, on data XX. HERX Lung Cancer September HERX patients. and Anderson poziotinib September, the in trial Conference the looking on and outstanding are lung on We populations. treated II Center. the both EGFR patient We're Medicine at quarter. presentation abstract to this cell forward our MD the Anderson presentation previously of updated MD World September approximately pleased studying in from data well sites they and multicenter the And with with was with others We second in non-small a XX Anderson's study process. are enrollment and in conducting also cohorts. at running several oral lead we MD of have in are cancer clinical published trial in Exciting both exon is currently underway. XX up Spectrum-sponsored The preclinical Phase and in the release mutations
us Europe by filings and Europe our productive poziotinib. United will partnership we The gaining access study to recent had globe have outside about most our first end guidance. in participating Phase the in the the that and the the discussion, sites activating fully FDA. enhance enroll encouraging well access of of will appreciate for was the development meeting registrational around patients II the this from and study an qualify process the on a the to with around patient interaction and as States. This is trial. in trial we regulatory ongoing expect in we're enthusiastic the for that Additionally, Investigators We been agency's believe year. of Based we position this very will world
poziotinib the criteria steadfast therapy breakthrough that need that Regarding unmet for over and medical substantial is believe a designation. demonstrates There existing BTD, is meets poziotinib our therapies. improvement clear belief we
with by the with our will the the the Anderson backbone FDA, of the forward clarity be As on MD our end discussions. of this gain data to we move year. expect pathway We conversations fully
So, here's unmet seen poziotinib medical what we area need. data of today. know early very high We've strong about in an
alignment agency Phase II shot and a have the our clear have trial we at We on with BTD.
Now, let's next. talk about what's
at look population. well benefits as full go we its the current targeted lung we in the therapy, believe cancer a As poziotinib beyond of previously-treated focus the potential
combination treatment naïve expanded focus of solid treatment key areas. line, other regimens cancer lung and the will first strategy tumors. Our three the The in patients on
into me get Let those. detail of more on each
to therapy. poziotinib first-line expansion as of is The explore first area a
patients EGFR II the XX cohorts and side poorly severe mutations. with limited efficacy. Phase naïve And standard of expand effects population. to HERX approved mutations, these our new care with no remains seem lung treatment also exon study respond are for immunotherapy. Currently, will current include for Chemotherapy the in to targeted patients EGFR We two therapies with they cancer to or there
We the year. patient the an fashion of the accelerated end have expect been in to this working enroll by on first and
area second with combination to in is of expansion The treatments. other poziotinib explore
synergistic The will drugs We to combination poziotinib toxicities. mechanisms to is outcomes. improve in with with look non-overlapping study focus to identify other
study initiated combination we've with T-DMX. For example, in dose-finding a
While is optimal these breast study the is dose of two combination identify this cancer, agents. to the overarching goal in
KOL that have are very several excited. other exploring logical we are there combinations and Additionally, the community
updated second initiating HERX XX This Anderson tumors. are at the These exon soon we mutations the The prevalent solid the AACR expansion? treatment is will prevalence see the keep a solid in progresses MD you strategy pan-tumor of that trial. this You quarter. be as area strategy In will other of way. to unfold tumors. and existing grounded cohort along year unveiled data data will demonstrated across poziotinib in final their
initiate will uncover expect Additionally, robust line potential pan-tumor to and full a its committed The we poziotinib's we to here, that after. are study have soon we bottom development. strategy Spectrum-sponsored, a basket
quarter. ROLONTIS. for two chemotherapy-induced talk novel, about is proprietary studied ROLONTIS neutropenia. in ROLONTIS utilizes and being had Now, which technology long-acting events GCSF key a the the in treatment second of is We let's
RECOVER, trial, III Phase primary endpoint. second its our efficacy First, met
MASCC. have demonstrated XXX-patient With we ROLONTIS in for detailed trial in was the safety program, presented at over Second, patients XXX robust profile. our advanced with data from pegfilgrastim Phase Vienna versus a III comparable DSN non-inferiority
with diligently to will BLA meeting we prepare forward, ensure with in we that team look As This as submission. to for agency FDA our work QX. pre-BLA QX the working we the in the meeting are our is alignment planned
ROLONTIS, look this a learned we've step I and about as back So, is what at what I take see.
strong effectively team a seasoned this data, multibillion-dollar comparable compete the to efficacy have with marketplace in safety novel a experience We agent with and market.
positive with in Our energy. operations full swing are
forward success to of focused both the We you back with providing as are year additional enthusiastic look poziotinib about and call the I'll Joe. and progresses our We the to updates ROLONTIS. over now turn business and on
